Inspire Medical Systems, Inc. to Report Third Quarter 2020 Financial Results on November 2, 2020

Rhea-AI Summary

Inspire Medical Systems, Inc. (NYSE: INSP) will release its third quarter 2020 financial results on November 2, 2020, post-market close. A conference call to discuss these results and recent business developments will begin at 5:00 PM Eastern Time. Inspire specializes in innovative solutions for obstructive sleep apnea, with its Inspire therapy being the first FDA-approved neurostimulation technology for moderate to severe cases. Details for joining the call and further information about the company are provided in the release.

Positive

• Inspire has developed the first FDA-approved neurostimulation technology for treating moderate to severe obstructive sleep apnea.
• Growth in the minimally invasive solutions market for patients with obstructive sleep apnea.

Negative

• None.

MINNEAPOLIS, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the third quarter 2020 after the close of trading on Monday, November 2. Inspire’s management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments.

Monday, November 2rd @ 5:00 p.m. Eastern Time:
Domestic:	877-407-0792
International:	201-689-8263
Conference ID:	13710653
Webcast:	http://public.viavid.com/index.php?id=141564

About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit www.inspiresleep.com.

Investor and Media Contact:
Bob Yedid
LifeSci Advisors
inspire@lifesciadvisors.com
646-597-6989

 

FAQ

When will Inspire Medical Systems release its third quarter 2020 earnings?

Inspire Medical Systems will release its third quarter 2020 financial results on November 2, 2020.

What is the conference call schedule for Inspire's Q3 financial results?

The conference call will begin at 5:00 PM Eastern Time on November 2, 2020.

What is the focus of Inspire Medical Systems?

Inspire Medical Systems focuses on developing innovative, minimally invasive solutions for obstructive sleep apnea.

What therapy does Inspire provide for obstructive sleep apnea?

Inspire provides the Inspire therapy, the first FDA-approved neurostimulation technology for obstructive sleep apnea.